Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.HCRI Expands DAPT Study Into Seven Countries In EU
The DAPT Study is a four-year clinical trial investigating the duration of dual antiplatelet therapy (DAPT, the combination of aspirin and a thienopyridine/antiplatelet medication to reduce the risk
The DAPT Study is a four-year clinical trial investigating the duration of dual antiplatelet therapy (DAPT, the combination of aspirin and a thienopyridine/antiplatelet medication to reduce the risk
The self-expanding Stentys stent is designed to ensure optimal apposition of a stent in the critical initial hours and days after an AMI (acute myocardial infarction) procedure, by
The acquisition of MUGI will allow Invida to leverage its full suite of capabilities throughout Indonesia and open up the Indonesian market for Invida’s partners, as well as
Kevetrin is being developed to treat drug resistant cancers. Cellceutix claimed that Kevetrin showed greater tumor growth delay than standard therapies in animal models of resistant lung cancer,
The contracts valued at approximately GBP330,000 in total, are for regulatory consultancy and follow on from the first contract for regulatory support signed in January this year. The
Blue Medical said that on placement of the stent a predetermined load of Paclitaxel will be delivered to the vessel wall to support the vessel in adapting to
Aspen is planning to acquire Sigma either directly or through a wholly-owned subsidiary. The amount set by Aspen includes A$707m in issued shares and A$785m in net debt,
Gabriele Lang, head of the division of medical retina and laser surgery of department of ophthalmology at University of Ulm in Germany, has presented the results from the
Novartis stated that following the EC’s decision, the pediatric indication needs to be implemented through EU National Competent Authorities before Diovan will be available for pediatric use across
According to Abviva, the Japanese Patent Office had issued two patents on the core breast cancer risk assessment technology that may be used for therapeutic applications and in